Download PDF
Thromb Haemost 1997; 77(05): 0815-0817
DOI: 10.1055/s-0038-1656058
Rapid Communications
Schattauer GmbH Stuttgart

Comparative Effects of Recombinant Staphylokinase and Streptokinase on Platelet Aggregation

Mustapha Abdelouahed
1   The Service d'Hématologie Biologique, Hôpital Hôtel-Dieu, Paris, France
,
Mohamed Hatmi
3   The Unité de Pharmacologie Cellulaire, Unité Associée Institut Pasteur-INSERM U285, Paris, France
,
Gérard Helft
2   The Clinique Cardiologique, Hôpital Necker, Paris, France
,
Sharareh Emadi
3   The Unité de Pharmacologie Cellulaire, Unité Associée Institut Pasteur-INSERM U285, Paris, France
,
Ismaïl Elalamy
1   The Service d'Hématologie Biologique, Hôpital Hôtel-Dieu, Paris, France
,
Meyer Michel Samama
1   The Service d'Hématologie Biologique, Hôpital Hôtel-Dieu, Paris, France
› Author Affiliations
Further Information

Publication History

Received 12 August 1996

Accepted after resubmission 04 February 1997

Publication Date:
11 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Recombinant staphylokinase (RSTA) has been shown to offer promise as a thrombolytic agent. In contrast to streptokinase (SK), few studies have been devoted to possible effects of RSTA on platelets. We have compared the capacity of RSTA and SK to trigger platelet aggregation and to modify ADP (2.5 µM) response in platelet-rich plasma (PRP) of 25 healthy subjects. Thus, exposure of PRP to SK (40 to 50 µg/ml) induced platelet aggregation in 6 out of 25 subjects. However, under the same conditions, RSTA failed to induce platelet aggregation in all cases (25 out of 25 subjects). In contrast to RSTA, SK (0.4 to 50 µg/ml) greatly reduced ADP-induced platelet aggregation in 12 out of 25 subjects. Preincubation of plasma with SK is associated with a decrease in the fibrinogen concentration. Furthermore, there was a good correlation between SK-induced fibrinogenolysis and SK- induced platelet aggregation defect (r2 = 0.9; p = 0.001). No fibrino genolysis was observed when different amounts of RSTA (0.4 to 50 µg/ml) were incubated in plasma for one min. However, there was a marked decrease in fibrinogen level (about 50%) when the plasma was incubated for five min with a very high concentration of RSTA. SK markedly enhanced the platelet response to ADP in 13 out of 25 subjects. In PRP of 6 out of 25 subjects, SK induces platelet aggregation and potentiates platelet response to ADP, however in PRP of 7 out of 25 subjects, SK caused only the increase of platelet response to ADP. The monoclonal antibody anti-FcγRIIal, IV-3 (2 [µ/ml), abolished SK-induced platelet aggregation and SK-enhanced ADP-induced platelet aggregation. In all cases (25 out of 25 subjects), RSTA failed to potentiate platelet response to ADP.

These findings confirm that RSTA has a lesser fibrinogenolytic ability than SK and suggest its negligeable effect on platelet function.

 

  • References

  • 1 Collen D, Silence K, Demarsin E, De MolM, Lijnen HR. Isolation and characterization of natural and recombinant staphylokinase. Fibrinolysis 1992; 6: 203-213
    PubMedGoogle Scholar
  • 2 Collen D, De CockF, Vanlinthout I, Declerck PJ, Lijnen HR, Stassen JM. Comparative thrombolytic and immunogenic properties of staphylokinase and streptokinase. Fibrinolysis 1992; 6: 232-242
    PubMedGoogle Scholar
  • 3 Lijnen HR, Stassen JM, Vanlinthout I, Fukao H, Okada K, Matsuo O, Collen D. Comparative fibrinolytic properties of staphylokinase and streptokinase in animal models of venous thrombosis. Thromb Haemost 1991; 66: 468-473
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Matsuo O, Okada K, Fukao H, Tomioka Y, Ueshima S, Watanuki M, Sakai M. Thrombolytic properties of staphylokinase. Blood 1990; 76: 925-929
    PubMedGoogle Scholar
  • 5 Coller BS. Platelet and thrombolytic therapy. N Engl J Med 1990; 332: 33-40
    PubMedGoogle Scholar
  • 6 Bertolino G, Noris P, Previtali M, Gamba G, Ferrario M, Montani N, Balduini CL. Platelet function after in vivo and in vitro treatment with thrombolytic agents. Am J Cardiol 1992; 69: 457-461
    CrossrefPubMedGoogle Scholar
  • 7 Abdelouahed M, Elalamy I, Lebrazi J, Helft G, Mirshahi M, Lecrubier C, Samama MM, Lecompte T. Streptokinase modifies in vitro platelet aggregation by two mechanisms: reduced aggregation due to fibrinogenolysis and enhanced aggregation via an immunological reaction. Platelets 1995; 6: 317-325
    CrossrefPubMedGoogle Scholar
  • 8 Lebrazi J, Abdelouahed M, Mirshahi M, Samama MM, Lecompte T. Streptokinase and APSAC inhibit platelet aggregation in vitro by fibrinogenolysis: effect of plasma fibrinogen degradation products X and E. Fibrinolysis 1995; 9: 113-119
    PubMedGoogle Scholar
  • 9 Gouin I, Lecompte T, Morel MC, Lebrazi J, Modderman PW, Kaplan C, Samama MM. In vitro effect of plasmin on human platelet function in plasma. Inhibition of aggregation caused by fibrinogenolysis. Circulation 1992; 85: 935-941
    CrossrefPubMedGoogle Scholar
  • 10 Fears R, Ferres H, Greenwood HC. Comparison of the effects of streptokinase, t-PA and APSAC on human platelet aggregation in vitro in absence and presence of aspirin. Thromb Res 1990; 60: 259-268
    CrossrefPubMedGoogle Scholar
  • 11 Torr SR, Winters KJ, Santoro SA, Sobel BE. The nature of interaction between tissue type plasminogen activator and platelets. Thromb Res 1990; 59: 279-293
    CrossrefPubMedGoogle Scholar
  • 12 Lebrazi J, Helft G, Abdelouahed M, Elalamy I, Mirshahi M, Samama MM, Lecompte T. Human anti-streptokinase antibodies induce platelet aggregation in an Fc receptor (CD32) dependent manner. Thromb Haemost 1995; 74: 938-942
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Vaughan DE, Van HoutteE, Declerck PJ, Collen D. Streptokinase induced platelet aggregation: Prevalence and mechanism. Circulation 1991; 84: 84-91
    CrossrefPubMedGoogle Scholar
  • 14 FitzGerald DJ, Catella F, Roy L, FitzGerald GA. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 1988; 77: 142-150
    CrossrefPubMedGoogle Scholar
  • 15 Born GVR, Cross MJ. The aggregation of blood platelets. J Physiol 1963; 168: 178-195
    CrossrefPubMedGoogle Scholar
  • 16 Von ClaussA. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-246
    CrossrefPubMedGoogle Scholar
  • 17 Collen D, De CockF, Stassen JM. Comparative immunogenicity and thrombolytic properties towards arterial and venous thrombi of streptokinase and recombinant staphylokinase in baboons. Circulation 1993; 87: 0996-1006
    CrossrefPubMedGoogle Scholar
  • 18 Vanderschueren S, Stockx L, Wilms G, Lacroix H, Verhaeghe R, Vermylen J, Collen D. Thrombolytic therapy of peripheral arterial occlusion with recombinant staphylokinase. Circulation 1995; 92: 2050-2057
    CrossrefPubMedGoogle Scholar
  • 19 Schlott B, Hartmann M, Gtihrs KH, Birch-Hirschfeld E, Pohl HD, Vanderschueren S, Van deWerf F, Michoel A, Collen D, Behnke D. High yield production and purification of recombinant staphylokinase for thrombolytic therapy. Biotechnology 1994; 12: 185-189
    CrossrefPubMedGoogle Scholar
  • 20 Collen D, Van deWerf F. Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction. Circulation 1993; 87: 1850-1853
    CrossrefPubMedGoogle Scholar
  • 21 Lijnen HR, Van HoefB, De CockF, Okada K, Ueshima S, Matsuo O, Collen D. On the mechanism of fibrin-specific plasminogen activation by staphylokinase. J Biol Chem 1991; 266: 11826-11832
    PubMedGoogle Scholar
  • 22 Lijnen HR, Van HoefB, Matsuo O, Collen D. On the molecular interactions between plasminogen-staphylokinase, α2-antiplasmin and fibrin. Biochem BiophysActa 1992; 1118: 144-148
    PubMedGoogle Scholar
  • 23 Suehiro A, Oura Y, Ueda M, Kakishita E. Inhibitory effects of staphylokinase on platelet aggregation. Thromb Haemost 1993; 70: 834-837
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Lijnen HR, Van HoefB, Collen D. Interactions of staphylokinase with human platelets. Thromb Haemost 1995; 73: 472-477
    Article in Thieme ConnectPubMedGoogle Scholar